Company: ARVN
Filing Date: 2025-05-01
Form Type: 8-K
Source: 0001655759-25-000081
Chunk: 2

Company: ARVINAS, INC.
Filing Date: 2025-05-01
Form: 8-K
Item: Item 8.01
Chunk 2
---
Item 8.01 Other Events.

On May 1, 2025, the Company announced that the Company and Pfizer, Inc., removed two planned Phase 3 combination trials of vepdegestrant from the agreed-upon joint development plan: a first-line Phase 3 combination trial with Pfizer’s novel investigational cyclin-dependent kinase, or CDK, 4 inhibitor, atirmociclib, and a second-line Phase 3 combination trial with a CDK4/6 inhibitor.

Item 9.01 Financial Statements and Exhibits.